Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence

Table 4

Total AEs (or SAEs) based on different afatinib dose (non-full dose vs. full-dose).

AEs (or SAEs)	Non-full dose		Full dose
	Total	Grade ≥3	Total	Grade ≥3
Diarrhea	55.8 (41.1, 70.0)%	1.0 (0.0, 7.4)%	94.7 (86.8, 99.5)%	9.8 (3.0, 19.3) %
Skin rashes	77.7 (64.2, 88.9)%	0.0 (0.0, 4.0) %	90.3 (80.9, 97.1)%	7.7 (1.7, 16.5) %
Mucositis	34.7 (21.4, 49.2)%	0.0 (0.0, 4.0) %	58.0 (44.9, 70.6)%	0.0 (0.0, 3.0) %
Paronychia	48.9 (34.4, 63.5)%	1.5 (0.0, 8.4) %	74.0 (61.7, 84.7) %	7.7 (1.7, 16.5) %
Dry skin	55.6 (40.9, 69.8)%	0.0 (0.0, 4.0) %	51.0 (38.0, 64.0) %	0.0 (0.0, 3.0) %
Pruritus	16.7 (6.9, 29.3)%	0.0 (0.0, 4.0) %	21.5 (11.6, 33.3) %	0.0 (0.0, 3.0) %

AEs, adverse events; SAEs, severe adverse events.